MX2012005447A - Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular. - Google Patents
Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular.Info
- Publication number
- MX2012005447A MX2012005447A MX2012005447A MX2012005447A MX2012005447A MX 2012005447 A MX2012005447 A MX 2012005447A MX 2012005447 A MX2012005447 A MX 2012005447A MX 2012005447 A MX2012005447 A MX 2012005447A MX 2012005447 A MX2012005447 A MX 2012005447A
- Authority
- MX
- Mexico
- Prior art keywords
- nsaid
- glaucoma
- treatment
- pharmaceutical combination
- ocular hypertension
- Prior art date
Links
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 title abstract 2
- -1 prostaglandin compound Chemical class 0.000 title abstract 2
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003655 bromfenac Drugs 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 abstract 1
- 229960002368 travoprost Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2761CH2009 | 2009-11-11 | ||
| PCT/IN2010/000717 WO2011058579A1 (en) | 2009-11-11 | 2010-11-01 | Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012005447A true MX2012005447A (es) | 2012-07-20 |
Family
ID=43587393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012005447A MX2012005447A (es) | 2009-11-11 | 2010-11-01 | Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120232140A1 (enExample) |
| EP (1) | EP2498768A1 (enExample) |
| JP (1) | JP2013510845A (enExample) |
| CN (1) | CN102711748A (enExample) |
| AU (1) | AU2010317390A1 (enExample) |
| BR (1) | BR112012010936A2 (enExample) |
| CA (1) | CA2780611A1 (enExample) |
| MX (1) | MX2012005447A (enExample) |
| RU (1) | RU2012124216A (enExample) |
| WO (1) | WO2011058579A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2852995C (en) * | 2011-10-12 | 2016-03-29 | Bausch & Lomb Incorporated | Ocular composition containing bromfenac with increased bioavailability |
| JP6185725B2 (ja) * | 2012-02-24 | 2017-08-23 | わかもと製薬株式会社 | 水性医薬組成物 |
| WO2021001806A1 (en) * | 2019-07-04 | 2021-01-07 | Ocular Discovery Ltd. | Stable dipyridamole formulations with reduced impurities |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631287A (en) * | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| US6011062A (en) * | 1994-12-22 | 2000-01-04 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| US6646001B2 (en) * | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| WO2004064828A1 (ja) * | 2003-01-21 | 2004-08-05 | Senju Pharmaceutical Co., Ltd. | ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤 |
| US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
-
2010
- 2010-11-01 CA CA2780611A patent/CA2780611A1/en not_active Abandoned
- 2010-11-01 AU AU2010317390A patent/AU2010317390A1/en not_active Abandoned
- 2010-11-01 CN CN2010800511948A patent/CN102711748A/zh active Pending
- 2010-11-01 WO PCT/IN2010/000717 patent/WO2011058579A1/en not_active Ceased
- 2010-11-01 EP EP10803392.9A patent/EP2498768A1/en not_active Withdrawn
- 2010-11-01 US US13/508,947 patent/US20120232140A1/en not_active Abandoned
- 2010-11-01 RU RU2012124216/15A patent/RU2012124216A/ru unknown
- 2010-11-01 MX MX2012005447A patent/MX2012005447A/es unknown
- 2010-11-01 JP JP2012538470A patent/JP2013510845A/ja not_active Withdrawn
- 2010-11-01 BR BR112012010936A patent/BR112012010936A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102711748A (zh) | 2012-10-03 |
| EP2498768A1 (en) | 2012-09-19 |
| WO2011058579A1 (en) | 2011-05-19 |
| JP2013510845A (ja) | 2013-03-28 |
| RU2012124216A (ru) | 2013-12-20 |
| US20120232140A1 (en) | 2012-09-13 |
| BR112012010936A2 (pt) | 2017-10-17 |
| CA2780611A1 (en) | 2011-05-19 |
| AU2010317390A1 (en) | 2012-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN06581A (enExample) | ||
| PH12013501579A1 (en) | Androgen composition for treating an opthalmic condition | |
| MY171920A (en) | Prevention and treatment of ocular conditions | |
| EA201070483A1 (ru) | Новые офтальмологические композиции | |
| EA201290191A1 (ru) | N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ | |
| MX339759B (es) | Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares. | |
| PH12013501256A1 (en) | Compositions and methods for modulating fxr | |
| TN2014000030A1 (en) | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators | |
| GEP20166474B (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| PH12014500179A1 (en) | Fixed dose combination of bimatoprost and brimonidine | |
| MX2010009570A (es) | Composiciones farmaceuticas que tienen una biodisponibilidad deseable. | |
| BR112013030554A2 (pt) | forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma | |
| MA35452B1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante | |
| TR201818754T4 (tr) | Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri | |
| EA201490222A1 (ru) | Комбинированные составы на основе дарунавира | |
| IN2014CN03123A (enExample) | ||
| EA201490223A1 (ru) | Составы на основе дарунавира | |
| GEP20156315B (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
| WO2012015998A3 (en) | Preservative free bimatoprost and timolol solutions | |
| TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
| WO2009109501A3 (en) | Ocular pharmaceutical compositions | |
| WO2012163827A3 (en) | Ophthalmic preparation comprising a pgf2alpha analogue | |
| BR112012017319A2 (pt) | composições e métodos para abaixar a pressão intraocular | |
| EA201400064A1 (ru) | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб |